Pemvidutide Research for MASH (Metabolic Dysfunction-Associated Steatohepatitis)
An overview of research and source records on Pemvidutide in the context of mash (metabolic dysfunction-associated steatohepatitis).
Research Summary
Phase 2 IMPACT trial (NCT05989711) met its MASH-resolution primary endpoint at 24 weeks: 52% MASH resolution without fibrosis worsening at 1.8 mg vs 20% placebo (and 58% at 1.2 mg). The co-primary fibrosis-improvement endpoint was not met at 24 weeks. CT.gov status checked 2026-09-28: COMPLETED, n=212 actual, hasResults false (published figures remain PMID 41237796). Phase 3 PERFORMA (NCT07795164) is recruiting (estimated n=1800; primary outcomes include a clinical-outcome event and histologic MASH-resolution / fibrosis-improvement co-responses). Rajab 2026 (PMID 41879841) pooled earlier MASLD/MASH RCTs (12-week liver-fat MD −52.90). FDA Fast Track designation granted November 2022.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.